Other Assets, Current, Fair Value Disclosure,

No definition available.

Name:	biib_OtherAssetsCurrentFairValueDisclosure
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair values as of the balance sheet date of all assets of deferred compensation plans.

+ References

No definition available.

+ Details

Name:	biib_PlanAssetsForDeferredCompensationFairValueDisclosure
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_AssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481830/320-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479130/326-30-45-1

+ Details

Name:	us-gaap_AvailableForSaleSecuritiesDebtSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

No definition available.

+ Details

Name:	us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.

+ References

No definition available.

+ Details

Name:	us-gaap_ForeignCurrencyContractAssetFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.

+ References

No definition available.

+ Details

Name:	us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value of financial and nonfinancial obligations.

+ References

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value portion of other assets.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Feb. 29, 2012
Assets:
Marketable debt securities		$ 2,179.2
Samsung Bioepis
Liabilities:
Ownership percentage			49.90%	15.00%
Fair value, measurements, recurring
Assets:
Cash equivalents	$ 610.7	2,847.6
Marketable equity securities	416.8	791.1
Derivative contracts	11.9	63.0
Plan assets for deferred compensation	37.5	32.8
Total	1,506.9	7,117.9
Liabilities:
Derivative contracts	31.6	26.0
Total	31.6	26.0
Fair value, measurements, recurring \| Samsung Bioepis
Assets:
Receivable from Samsung BioLogics	430.0	798.8
Receivable from Samsung BioLogics		405.4
Fair value, measurements, recurring \| Corporate debt securities
Assets:
Marketable debt securities		1,231.6
Fair value, measurements, recurring \| Government securities
Assets:
Marketable debt securities		810.3
Fair value, measurements, recurring \| Mortgage and other asset backed securities
Assets:
Marketable debt securities		137.3
Quoted Prices in Active Markets (Level 1) \| Fair value, measurements, recurring
Assets:
Cash equivalents	0.0	0.0
Marketable equity securities	416.8	791.1
Derivative contracts	0.0	0.0
Plan assets for deferred compensation	0.0	0.0
Total	416.8	791.1
Liabilities:
Derivative contracts	0.0	0.0
Total	0.0	0.0
Quoted Prices in Active Markets (Level 1) \| Fair value, measurements, recurring \| Samsung Bioepis
Assets:
Receivable from Samsung BioLogics	0.0	0.0
Receivable from Samsung BioLogics		0.0
Quoted Prices in Active Markets (Level 1) \| Fair value, measurements, recurring \| Corporate debt securities
Assets:
Marketable debt securities		0.0
Quoted Prices in Active Markets (Level 1) \| Fair value, measurements, recurring \| Government securities
Assets:
Marketable debt securities		0.0
Quoted Prices in Active Markets (Level 1) \| Fair value, measurements, recurring \| Mortgage and other asset backed securities
Assets:
Marketable debt securities		0.0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, recurring
Assets:
Cash equivalents	610.7	2,847.6
Marketable equity securities	0.0	0.0
Derivative contracts	11.9	63.0
Plan assets for deferred compensation	37.5	32.8
Total	660.1	5,122.6
Liabilities:
Derivative contracts	31.6	26.0
Total	31.6	26.0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, recurring \| Samsung Bioepis
Assets:
Receivable from Samsung BioLogics	0.0	0.0
Receivable from Samsung BioLogics		0.0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, recurring \| Corporate debt securities
Assets:
Marketable debt securities		1,231.6
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, recurring \| Government securities
Assets:
Marketable debt securities		810.3
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, recurring \| Mortgage and other asset backed securities
Assets:
Marketable debt securities		137.3
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, recurring
Assets:
Cash equivalents	0.0	0.0
Marketable equity securities	0.0	0.0
Derivative contracts	0.0	0.0
Plan assets for deferred compensation	0.0	0.0
Total	430.0	1,204.2
Liabilities:
Derivative contracts	0.0	0.0
Total	0.0	0.0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, recurring \| Samsung Bioepis
Assets:
Receivable from Samsung BioLogics	$ 430.0	798.8
Receivable from Samsung BioLogics		405.4
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, recurring \| Corporate debt securities
Assets:
Marketable debt securities		0.0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, recurring \| Government securities
Assets:
Marketable debt securities		0.0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, recurring \| Mortgage and other asset backed securities
Assets:
Marketable debt securities		$ 0.0